Popular Media
-
The 30-year-old female founder at the forefront of a billion-dollar bet on CRISPR gene editing
CNBCLearn More -
Venture Investment in Crispr Gene Editing Spurs Innovation, Hunt for IP
Wall Street JournalLearn More -
Bayer jumps on board Mammoth’s ultra-small CRISPR tech with sights set first on liver disease
Endpoints NewsLearn More -
Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
STAT NewsLearn More -
Mammoth Biosciences Inks 691 Million Deal to Develop Crispr Gene Editing Therapies
ForbesLearn More -
Vertex signs another Mammoth-sized CRISPR deal with $650M in biobucks on the line
Fierce BiotechLearn More -